Power to the Patients

Episode #1: Patient-centered design with Scott Schliebner, former SVP at ICON

Power to the Patients Off Script with Scott Schliebner Episode Artwork

Episode Description

Listen to this episode on:

In this episode, Scott Schliebner, a life sciences and digital health executive with experience across the biopharma, CRO, medtech, and non-profit sectors, discusses the evolution of patient-centricity. With over 30 years of experience, Scott provides insights into patient-centered design in clinical research. 

The discussion also covers the necessity of using more humanizing terms for patients, the crucial balance in patient recruitment, the role of patient advocacy, and the future of the industry.

Topics discussed:

  • Introduction to Scott Schliebner, a life sciences and digital health executive
  • Evolution of patient involvement in clinical research
  • Discussion on the current state of the industry and areas for improvement
  • Introduction to Power's platform, designed to streamline interactions between patients and researchers
  • Future developments in healthcare and the role of patient-centricity
  • Consideration of the administrative burden of clinical trials and potential ways to accelerate the process
  • Importance of building relationships with advocacy groups and providing a range of clinical trial opportunities for patients
  • Closing remarks on the future of patient-centricity in clinical research, and an invitation to listeners to join the ongoing conversation

About the podcast

Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation.

Power is a modern clinical trial marketplace. We help patients access research and help trials recruit more patients.

Subscribe to get notified when new episodes are released.